【レポートの概要（一部）】
1. Report Overview
1.1 Global Dermatological Drugs: Market Overview
1.2 Global Dermatological Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction To Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction To Dermatology
2.2.1 The Structural Lay-out Of The Skin, Hair, And Nails
2.2.2 Hair And Nails
2.2.3 Sweat And Sebaceous Glands
2.2.4 Functions Of The Skin
2.3 Common Skin Diseases
2.4 Acne: The Most Common Skin Disease
2.4.1 Acne: Epidemiology
2.4.2 Acne: Causes And Pathogenesis
2.4.3 Acne: Treatment
2.5 Dermatitis: Inflammation Of The Skin
2.5.1 Atopic Dermatitis
2.5.2 Contact Dermatitis
2.5.3 Seborrhoeic Dermatitis
2.5.4 Nummular Dermatitis
2.5.5 Perioral Dermatitis
2.6 Psoriasis: A Complex Multi-factorial Disease
2.7 Rosacea: Vascular Instability
2.8 Alopecia: Excessive Shedding Of Hair
2.9 Skin Infections: A Serious Healthcare Threat
2.9.1 Bacterial Skin Infections
2.9.2 Fungal Skin Infections
2.9.3 Viral Skin Infections
2.10 Common Skin Treatments
2.10.1 Creams and Semisolid Emulsions
2.10.2 Ointments
2.10.3 Lotions
2.10.4 Solutions
2.10.5 Occlusive Therapy
2.10.6 Cleansing Agents
2.10.7 Powders and Hydrophilic Polymer
2.10.8 Anti-Infective Agents
2.10.9 Anti-Inflammatory Agents
2.11 Phases Of Clinical Trials
2.12 Dermatological Drugs: Market Definition In This Report
3. The Global Dermatological Drugs Market, 2015-2025
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation Of The Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market In 2014
3.4 The Global Dermatological Drugs Market: Market Forecast 2015-2025
3.5 Dermatological Drugs: Changing Market Shares By Sector 2015-2025
4. The Psoriasis Drugs Market: Market Analysis And Forecast 2015-2025
4.1 Psoriasis Treatments: The Dominance Of Biologics
4.1.1 Leading Products In The Psoriasis Drugs Market, 2014
4.2 Psoriasis: Market Trends And Developments, 2015
4.2.1 Biological Drugs In Psoriasis Treatment: A Brief Overview
4.2.2 Issues Around Patent Protection, The Threat Of Biosimilars And Pricing
4.2.3 The Disadvantages Of Biologics In Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2015-2025
4.3.1 Psoriasis Drugs: Changing Market Shares By Leading Drugs 2015-2025
4.4 Leading Drugs Used In The Treatment Of Psoriasis
4.5 Humira (adalimumab) – AbbVie
4.5.1 Humira: Historical Sales Analysis, 2010-2014
4.5.2 Humira: Sales Forecast 2015-2025
4.5.3 Future Prospects For Biosimilar Versions Of Humira
4.6 Stelara (ustekinumab) – Johnson & Johnson
4.6.1 Stelara: Historical Sales Analysis, 2010-2014
4.6.2 Stelara: Sales Forecast 2015-2025
4.6.3 Intensifying Competition For Stelara
4.7 Enbrel (etanercept) – Amgen/ Pfizer/ Takeda
4.7.1 Enbrel: Co-Promotions And Marketing Rights
4.7.2 Enbrel: Historical Sales Analysis, 2008-2014
4.7.3 Enbrel: Patent Expiries and Potential Competition, 2015-2025
4.7.4 Enbrel: Sales Forecast 2015-2025
4.7.5 Enbrel Auto-injector Pens: A Driver Of Growth In Recent Years
4.7.6 Competition From Other Drugs
4.7.7 Biosimilar Competition For Enbrel
4.8 Remicade (infliximab) – Johnson & Johnson
4.8.1 Remicade: Historical Sales Analysis, 2010-2014
4.8.2 Remicade: Patent Expiries and Potential Competition, 2015-2025
4.8.3 Remicade: Sales Forecast 2015-2025
4.9 Daivobet (betamethasone/calcipotriene) – LEO Pharma
4.9.1 Daivobet: Sales Forecast 2015-2025
4.9.2 LEO Pharma’s Life Cycle Management Of Daivobet
4.9.3 Daivobet/Dovobet/Taclonex – Generic Competition
4.10 Soriatane (acitretin) – GlaxoSmithKline
4.10.1 Soriatane: Sales Forecast 2015-2025
4.11 Other Psoriasis Drugs
4.11.1 Cimzia (certolizumab) – UCB
4.11.2 Cosentyx (secukinumab) – Novartis
4.11.3 Otezla (apremilast) – Celgene
4.11.4 Sorilux (calcipotriene foam) – GSK
4.11.5 Other Psoriasis Drugs: Sales Forecast 2015-2025
4.12 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis And Forecast 2015-2025
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products In The Skin Infection Drugs Market, 2014
5.2 Skin Infection Drugs: Market Forecast 2015-2025
5.2.1 Skin Infection Drugs: Changing Market Shares By Leading Drugs 2015-2025
5.3 Leading Drugs Used In The Treatment Of Skin Infections
5.4 Cubicin (daptomycin) – Cubist Pharmaceuticals/ Merck & Co
5.4.1 Acquisition By Merck & Co
5.4.2 Generic Competition For Cubicin
5.4.3 Cubicin: Sales Forecast 2015-2025
5.4.4 Lifecycle Management Strategies For Cubicin
5.5 Zyvox (linezolid) – Pfizer
5.5.1 Zyvox: Historical Sales Analysis, 2010-2014
5.5.2 Zyvox: Sales Forecast 2015-2025
5.5.3 The Threats To Zyvox Sales From Competing New Drugs
5.6 Valtrex (valaciclovir) – GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2014
5.6.2 Valtrex: Sales Forecast 2015-2025
5.7 Canesten (clotrimazole) – Bayer
5.7.1 Canesten: Historical Sales Analysis, 2011-2014
5.7.2 Canesten: Sales Forecast 2015-2025
5.8 Lamisil (terbinafine) – Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2015-2025
5.9 Bactroban (mupirocin) – GSK
5.9.1 Bactroban: Historical Sales Analysis, 2010-2013
5.9.2 Bactroban: Sales Forecast 2015-2025
5.10 Other Skin Infection Drugs
5.10.1 Dalvance (dalbavancin) – Durata Therapeutics
5.10.2 Jublia (efinaconazole) – Valeant
5.10.3 Kerydin (tavaborole) – Anacor
5.10.4 Sivextro (tedizolid) – Cubist Pharmaceuticals
5.10.5 Zovirax (acyclovir) – Valeant/GSK
5.10.5.1 Valeant Acquires Zovirax In US And Canada
5.10.5.2 Mylan’s Generic Zovirax And Actavis’ Authorised Generic
5.10.6 Other Skin Infection Drugs: Sales Forecast 2015-2025
5.11 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis And Forecast 2015-2025
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products In The Acne Drugs Market, 2014
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise Of Combination Therapies In Acne Treatment
6.2.2 Oral Contraceptives In Treating Acne
6.2.3 The Threat Of Generic Competition In The Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2015-2025
6.3.1 Acne Drugs: Changing Market Shares By Leading Drugs 2015-2025
6.4 Leading Drugs In The Acne Drugs Market
6.5 Solodyn (minocycline) – Valeant
6.5.1 Solodyn: Sales Forecast 2015-2025
6.5.2 Antitrust Action Over Solodyn Pay-For-Delay Deals
6.5.3 Impax And Medicis Collaborating On Advanced Solodyn
6.5.4 Medicis And Lupin Settle
6.6 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health
6.6.1 Epiduo: Sales Forecast 2015-2025
6.6.2 Galderma Settlement Agreement Over Generic Epiduo
6.6.3 Paediatric Approval For Epiduo
6.7 Claravis (isotretinoin) – Teva
6.7.1 Claravis: Sales Forecast 2015-2025
6.8 Aczone (dapsone) – Allergan
6.8.1 Aczone: Sales Forecast 2015-2025
6.9 Differin (adapalene) – Galderma/ Nestlé Skin Health
6.9.1 Recent Generic Competition To Differin
6.9.2 Differin: Sales Forecast 2015-2025
6.9.3 Federal Circuit Court Invalidates Differin Patents
6.10 Absorica/Epuris (CIP-isotretinoin) – Cipher/ Sun Pharma
6.10.1 Absorica/Epuris: Sales Forecast 2015-2025
6.11 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International
6.11.1 Valeant’s Patent Settlement With Actavis Over Ziana
6.11.2 Ziana: Sales Forecast 2015-2025
6.12 Doryx (doxycycline) – Actavis/ Mayne Pharma
6.12.1 Lifecycle Management Strategies For Doryx
6.12.2 Divestment Agreement With Mayne Pharma
6.12.3 Generic Competition For Doryx
6.12.4 Doryx: Sales Forecast 2015-2025
6.13 Other Acne Drugs
6.13.1 Acanya (clindamycin/benzoyl peroxide) – Dow / Valeant
6.13.1.1 Acanya: Financial Analysis
6.13.1.2 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
6.13.1.3 Legal Battles Involving Dow/Valeant, Perrigo, And Watson
6.13.2 Amnesteem (isotretinoin) – Mylan
6.13.2.1 Amnesteem: Financial Analysis
6.13.3 Diane (cyproterone/ethinyl estradiol) – Bayer
6.13.4 Duac (clindamycin/benzoyl peroxide) – GlaxoSmithKline
6.13.4.1 Duac: Financial Analysis
6.13.5 Veltin (tretinoin/clindamycin) – GSK
6.13.6 Other Acne Drugs: Sales Forecast 2015-2025
6.14 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis And Forecast 2015-2025
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products In The Dermatitis Drugs Market, 2014
7.2 Dermatitis Drugs: Market Forecast 2015-2025
7.2.1 Dermatitis Drugs: Changing Market Shares By Leading Drugs 2015-2025
7.3 Leading Drugs In The Dermatitis Drugs Market
7.4 Bepanthen (dexpanthenol)/ Bepanthol – Bayer
7.4.1 Bepanthen: Sales Forecast 2015-2025
7.5 Protopic (tacrolimus) – Astellas Pharma/ Roche
7.5.1 Protopic Benefits From Expanded Indication
7.5.2 Generic Competition For Protopic
7.5.3 Protopic: Sales Forecast 2015-2025
7.6 Elidel (pimecrolimus) – Meda Pharma/ Valeant
7.6.1 Elidel: Sales Forecast 2015-2025
7.7 Elocon (mometasone) – Merck & Co
7.7.1 Elocon: Sales Forecast 2015-2025
7.8 Other Dermatitis Drugs: Sales Forecast 2015-2025
7.9 Dermatitis Drugs: Market Outlook
8. Leading National Markets For Dermatological Drugs, 2015-2025
8.1 The Dermatological Drugs Market By Region
8.1.1 The Global Distribution Of Dermatological Drugs In 2014
8.2 Leading National Markets: Forecast 2015-2025
8.2.1 Changing Market Shares By Region, 2015-2025
8.3 Regional Dermatological Drugs Markets: Analysis And Forecasts, 2015-2025
8.4 United States: The Largest Dermatological Drugs Market
8.4.1 The Impact Of An Expanding Medicare Coverage
8.4.2 Legislative Environment Stimulating Biosimilars Market?
8.4.3 US Dermatological Drugs Market: Market Forecast 2015-2025
8.5 The EU5 Markets: Growth Expected In Each Country
8.5.1 EU5 Dermatological Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025
8.5.2 Germany
8.5.2.1 German Dermatological Drugs Market: Market Forecast 2015-2025
8.5.3 France
8.5.3.1 French Dermatological Drugs Market Forecast 2015-2025
8.5.4 UK
8.5.4.1 UK Dermatological Drugs Market Forecast 2015-2025
8.5.5 Italy
8.5.5.1 Italian Dermatological Drugs Market Forecast 2015-2025
8.5.6 Spain
8.5.6.1 Spanish Dermatological Drugs Market Forecast 2015-2025
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Dermatological Drugs Market Forecast 2015-2025
8.7 China
8.7.1 Expansion Of Healthcare Coverage And Reimbursement In China
8.7.2 Improving Public Perception Of Dermatology In China
8.7.3 Price Controls And The Anhui Model
8.7.4 Chinese Dermatological Drugs Market Forecast 2015-2025
8.8 India
8.8.1 The Effects Of The Drug Prices Control Order Of 2013
8.8.2 India’s Expansion Of Healthcare Provision
8.8.3 Indian Dermatological Drugs Market Forecast 2015-2025
8.9 Brazil
8.9.1 The Growth In Brazil’s Healthcare Landscape
8.9.2 Clearer Access To Medicines In Brazil
8.9.3 Brazilian Dermatological Drugs Market Forecast 2015-2025
8.10 Russia
8.10.1 Pharma2020 Strategy – Healthcare And Industry Reform
8.10.2 Russian Dermatological Drugs Market Forecast 2015-2025
8.11 Mexico
8.11.1 Seguro Popular: Mexican Healthcare Reform
8.11.2 Are Multinationals Waking Up To Mexico’s Potential?
8.11.3 Mexican Dermatological Drugs Market Forecast 2015-2025
8.12 Rest of the World
8.12.1 The Rest of the World Dermatological Drugs Market Forecast 2015-2025
9. Leading Companies In The Dermatological Drugs Market, 2015-2025
9.1 Dermatological Drugs – A Rapidly Consolidating Market
9.2 Galderma (Nestle Skin Health S.A.)
9.2.1 Galderma: Dermatological Drugs Portfolio, 2015
9.2.2 Galderma: Recent Developments
9.2.2.1 Nestlé’s Acquisition Of Galderma
9.2.2.2 Approval Of Soolantra For Rosacea
9.2.2.3 Mirvaso Launched For Rosacea
9.3 Johnson & Johnson
9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2015
9.3.2 Johnson & Johnson Dermatological Drugs Sales Forecast 2015-2025
9.3.3 Johnson And Johnson: Dermatological Drug Development Efforts, 2015
9.4 AbbVie
9.4.1 AbbVie: Dermatological Drugs Portfolio, 2015
9.4.2 AbbVie Dermatological Drugs Sales Forecast 2015-2025
9.4.3 AbbVie: Dermatological Drugs Development Pipeline, 2015
9.4.3.1 BT-061 (tregalizumab) For The Treatment Of Psoriasis
9.5 GlaxoSmithKline (GSK)
9.5.1 GSK: Dermatological Drugs Portfolio, 2015
9.5.2 GlaxoSmithKline (GSK) Dermatological Drugs Sales Forecast 2015-2025
9.5.3 GlaxoSmithKline (GSK): Recent Developments
9.5.3.1 Business Restructuring Arrangements With Novartis
9.5.3.2 Tafinlar and Mekinist Combination Approved by FDA, Withdrawn in EU
9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2015
9.6 Pfizer
9.6.1 Pfizer: Dermatological Drugs Portfolio, 2015
9.6.2 Pfizer Dermatological Drugs Sales Forecast 2015-2025
9.6.3 Pfizer: Dermatological Drugs Development Pipeline, 2015
9.7 LEO Pharma
9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2015
9.7.2 LEO Pharma Dermatological Drugs Sales Forecast 2015-2025
10. Dermatological Drugs: Research And Development Pipeline, 2015-2025
10.1 Innovative Products Currently In Development Will Drive Growth
10.1.1 New Technology In R&D Pipeline Activities
10.1.1.1 Reformulation
10.1.1.2 Combination Treatments
10.1.1.3 New Mechanisms And Drug Delivery Technologies
10.1.1.4 Potential Market Entrants
10.2 Psoriasis Drugs Development Pipeline, 2015
10.2.1 Psoriasis Drugs In Phase 3 Development
10.2.1.1 000-0551 Lotion (halobetasol) – Therapeutics, Inc
10.2.1.2 AMG 827 (brodalumab) – AstraZeneca/ Amgen
10.2.1.3 CF101 (IB-MECA) – Can-Fite BioPharma
10.2.1.4 CNTO 1959 (guselkumab) – MorphoSys/ Janssen
10.2.1.5 LAS41008 (dimethyl fumarate) – Almirall
10.2.1.6 LEO 90100 – LEO Pharma
10.2.1.7 LY2439821 (ixekizumab) – Eli Lilly
10.2.1.8 MK-3222/SCH 900222 (tildrakizumab) – Merck
10.2.1.9 STF 115469 (calcipotriene foam) – GSK
10.2.1.10 Xeljanz (tofacitinib) – Pfizer
10.2.2 Psoriasis Drugs In Phase 2 Development
10.2.2.1 AN2728 (PDE-4 inhibitor) – Anacor Pharmaceuticals
10.2.2.2 CT327 (TrkA inhibitor) – Creabilis Therapeutics
10.2.2.3 ASP015K (JAK inhibitor) – Astellas Pharma
10.2.2.4 Jakavi/Jakafi (ruxolitinib) – Incyte/ Novartis
10.2.2.5 LY3009104 (baricitinib) – Incyte/ Eli Lilly
10.2.2.6 PH-10 (Rose Bengal) – Provectus Biopharmaceuticals
10.2.3 Psoriasis Drugs In Phase 1 And Pre-clinical Development
10.3 Skin Infection Drugs Development Pipeline, 2015
10.3.1 Drugs In Phase 3 Development For Skin Infections
10.3.1.1 Delafloxacin (delafloxacin) – Melinta Pharmaceuticals
10.3.1.2 NB-001 – NanoBio Corporation
10.3.1.3 Orbactiv/ Nuvocid (oritavancin) – The Medicines Company
10.3.1.4 Luliconazole – Topica Pharmaceuticals
10.3.2 Drugs In Phase 2 Development For Skin Infections
10.3.3 Drugs In Phase 1 And Preclinical Pipeline For Skin Infections
10.4 Acne Drugs Development Pipeline, 2015
10.4.1 Drugs In Phase 3 Development For Acne
10.4.1.1 Duac low dose (clindamycin/ benzoyl peroxide) – GlaxoSmithKline
10.4.1.2 Visonac (photodynamic therapy) – Photocure
10.4.2 Drugs In Phase 2 Development For Acne
10.4.3 Drugs In Phase 1 And Pre-clinical Development For Acne
10.4.4 A Possible Vaccine For Acne
10.5 Dermatitis Drugs Development Pipeline, 2015
10.5.1 Drugs In Phase 3 Development For Dermatitis
10.5.1.1 Toctino (alitretinoin) – GSK
10.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher Pharmaceuticals
10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) – Pierre Fabre
10.5.1.4 REGN668/SAR231893 (dupilumab) – Regeneron/ Sanofi
10.5.1.5 Soriatane (acitretin) – InnovaDerm/Tribute Pharmaceuticals
10.5.2 Drugs In Phase 2 Development For Dermatitis
10.5.3 Drugs In Phase 1 And Preclinical Stages Of Development For Dermatitis
10.6 Other Dermatological Drugs Development Pipeline, 2015
10.6.1 Other Dermatological Drugs: Filed or Recently Launched
10.6.1.1 Actikerall (fluorouracil/salicylic acid) – Almirall
10.6.1.2 Ameluz (5-ALA photodynamic therapy) – Biofrontera
10.6.1.3 Keytruda (MK-3475, Pembrolizumab) – Merck
10.6.1.4 Mirvaso (brimonidine) – Galderma
10.6.1.5 Picato (ingenol mebutate) – LEO Pharma
10.6.1.6 Xolair (omalizumab) – Novartis/ Roche
10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2015
10.6.2.1 Atralin (tretinoin) – Valeant
10.6.2.2 BMS-936558 (nivolumab) – Bristol-Myers Squibb
10.6.2.3 CD5024 (ivermectin) – Galderma
10.6.2.4 Latisse (bimatoprost) – Allergan (Actavis)
10.6.2.5 LEE011, LGX818, and MEK162 – Novartis
10.6.2.6 Oleogel-S10 (triterpene extract) – Birken AG
10.6.2.7 PV-10 (Rose Bengal) – Provectus Pharmaceuticals
10.6.2.8 SR-T100 gel (Solanum incanum extract) – G&E Herbal Biotechnology
10.6.2.9 TVEC (talimogene laherparepvec) – Amgen
10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2015
10.6.4 Other Dermatological Drugs: Phase 1 and Preclinical Pipeline
11. Qualitative Analysis Of The Dermatological Drugs Market, 2015-2025
11.1 Market Factors Influencing Dermatological Drugs
11.2 SWOT Analysis Of The Global Dermatological Drugs Market, 2015-2025
11.2.1 Strengths
11.2.1.1 The High Unmet Clinical Need In Dermatology
11.2.1.2 A Healthy Pipeline Of Development-Stage Products
11.2.1.3 Strong Industry-Physician Relationships
11.2.2 Weaknesses
11.2.2.1 Limited Efficacy And Adverse Effects May Impact Product Uptake
11.2.2.2 Patient Adherence – A Major Challenge To Treatment Design
11.2.2.3 Impending Patent Expiries And The Challenges Posed By Generic Competition
11.2.3 Opportunities
11.2.3.1 The High-Growth Sectors In Dermatology
11.2.3.2 Personalised Dermatology: Technological Advances In Genomics
11.2.3.3 Advances In Topical Drug Delivery Methods Offers Product Differentiation
11.2.3.4 Consolidation Within Dermatology – Opportunity For Synergistic Growth?
11.2.4 Threats
11.2.4.1 Uncertain Surrounding Reimbursement And Payment Approvals
11.2.4.2 The Rising Cost Of Research And Development
11.2.4.3 Downward Pressures On Drug Prices
11.3 Porter’s Five Force Analysis Of The Global Dermatological Drugs Market, 2015-2025
11.3.1 Threat Of New Entrants
11.3.2 Threat Of Substitutes
11.3.3 Rivalry Among Competitors
11.3.4 Power Of Buyers
11.3.5 Power Of Suppliers
12. Expert Opinions from Our Primary Research
12.1 Interview With Kathleen Deardorff, Chief Operating Officer At Photocure ASA
12.1.1 Visonac As An Innovative First-In-Class Treatment
12.1.2 Photocure’s Development Plans For Visonac
12.1.3 Commercialisation Strategy For Visonac
12.1.4 On The Geographical Reach Of Acne Treatments
12.1.5 The Key Unmet Needs Within Patient Populations For Acne
12.1.6 The Key Forces Driving And Restraining The Development Of Acne Therapies
12.1.7 On The Current Development Pipeline For Acne Therapies
12.1.8 On Photocure’s Plans For Future Growth
12.1.9 Future Prospects For The Acne Treatments Market
13. Conclusions
13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
13.2 Leading Sectors In Dermatological Drugs In 2014
13.3 Leading Regions In The Dermatological Drugs Market In 2014
13.4 Future Outlook For The Various Sectors Within The Dermatological Drugs Market, 2015-2025
13.5 What Does The Future Hold For Dermatological Drugs?
【レポート販売概要】
■ タイトル：皮膚科用薬剤の世界市場：皮膚感染症薬、皮膚炎薬、にきび薬、乾癬薬■ 英文：Dermatological Drugs Market Forecast 2015-2025 : Opportunities for Leading Companies
■ 発行日：2015年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN5052605
■ 調査対象地域：グローバル
- モノクロル酢酸の世界市場2015-2019About MCAA MCAA, also called chloroacetic acid, is a bi-functional molecule-structured acid. It is extensively used as a chemical intermediate for the production of numerous industrially and commercially important chemicals, including glycine, CMC, TGA, and cyanoacetic acid. It is also used in the production of betaine-type surfactants, synthetic caffeine, and vitamins, and the production of 2,4-D …
- エンターテインメント及びメディア産業年鑑2015PLUNKETT'S ENTERTAINMENT & MEDIA INDUSTRY ALMANAC 2015 Key Findings: • Plunkett Research lists top 400 companies in Entertainment & Media and names top trends changing the industry for the mid term. Key Features: • Industry trends analysis, market data and competitive intelligence • Market forecasts and Industry Statistics • Industry Associations and Professional Societies List • In-Depth Profiles …
- エポキシ樹脂の世界市場：インサイト、市場機会、市場シェア、市場予測The global epoxy resins market is estimated to reach $12.15 billion by 2022 and is expected to grow at CAGR of 9.6% during 2016-2022. The Epoxy resins market is segmented on the basis of application and geography. The application segment is further segmented into adhesives, composites, construction, electrical & electronics, other applications, paints & coatings, wind turbine. The composites mater …
- MDU Resources Group, Inc.：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013MDU Resources Group, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary MDU Resources Group, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essentia …
- 神経内分泌系癌：世界の臨床試験レビュー（2014年上半期）Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" provides data on the Neuroendocrine Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Cancer. It includes an overview of the trial numbers and the …
- 高温断熱材の世界市場：セラミックファイバー、耐火断熱煉瓦About HTI Materials HTI products are used for application requiring high temperature, which is more than 1,000 c. The major function of HTI products is to conserve energy by reducing heat loss, controlling surface temperature, increasing operating efficiency of ventilation and reducing or preventing the damage of equipment. HTI products comprise of two major products: ceramic fiber and IFB. The ke …
- 世界の整形外科用バイオマテリアル（生体材料）市場：移植骨、機械加工骨、DBM、BMP（骨形成タンパク質)などAbout Orthopedic Biomaterial Orthopedic biomaterial deals with the physical and chemical properties of the material that is implanted into the human body as constituents of devices. The material implanted is designed to perform specific biological functions by substituting or repairing the damaged tissues such as cartilage, bone, ligaments, and tendons. Bone and joint-related degenerative problems …
- 固体経口剤形（OSDF）賦形剤の世界市場About OSDF Excipients OSDF excipients are chemical compounds that are added along with API and other chemicals during the manufacture of a drug. The sole purpose of the excipients is to hold the components together in the different forms of oral dosage. Sometimes, these excipients also act as drug releasers by releasing controlled amount of the medication after ingestion of the same. The global OS …
- 米バイオ燃料市場分析：Analyzing Biofuels from RiceHistory has seen fuel innovations being driven majorly by transportation needs rather than the overall need to revolutionize the energy needs of the society. It has also been very evident that biofuels have been treated more as a cost variant to high crude oil prices rather than a serious energy alternative. However with the advent of new economies which have now begun to realize their worst energ …
- Talisman Energy Inc.：石油・ガスの開発・生産動向及びコスト分析- Q1, 2013Talisman Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary Talisman Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source f …
- 世界の企業NAS（Network Attached Storage）市場動向（2014-2018）About Enterprise NAS A NAS device is a computer storage device that is connected to a network to provide data storage and data retrieval/file-sharing services for heterogeneous clients and authorized network users. NAS devices allow several computers to simultaneously share the same storage space. By connecting a high-capacity NAS device to a network, all devices/computers in the network can easil …
- 超高圧(EHV)送電の世界市場：超高圧送電線、変電所設備This report estimates the global EHV transmission market in terms of volume and value. It also estimates the market size of EHV transmission market for transmission line equipment: transmission towers and substation: transformers. The study has been broken down as per system and geography. The leading market for EHV transmission is Asia-Pacific due to higher demand for power requirement, followed …
- Lupuzor (Systemic Lupus Erythematosus and Lupus Nephritis)：市場予測と分析（～2022）Lupuzor (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvemen …
- 分子診断のグローバル市場：新技術、最新検査、市場予測、競争優位This new seven-country study from Venture Planning Group contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years. Highlights- Business and technological trends in seven major markets: France, Germany, Italy, Japa …
- 小売向けディスプレイの世界市場2016-2020About Retail Display Displays are used to exhibit data or information. They are referred to as retail displays when used in retail applications like POS systems, kiosks, ATMs, and digital signage. They can be both touch-enabled and non-touch displays. A growing number of retailers are using interactive displays to attract customers. Retailers have to make sure that their digital displays are techn …
